| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11413360 | BLUE EARTH | Dual mode radiotracer and—therapeutics |
Nov, 2038
(14 years from now) | |
Posluma is owned by Blue Earth.
Posluma contains Flotufolastat F-18 Gallium.
Posluma has a total of 1 drug patent out of which 0 drug patents have expired.
Posluma was authorised for market use on 25 May, 2023.
Posluma is available in solution;intravenous dosage forms.
Posluma can be used as positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (psa) level.
Drug patent challenges can be filed against Posluma from 26 May, 2027.
The generics of Posluma are possible to be released after 22 November, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...
Dosage: SOLUTION;INTRAVENOUS
POSLUMA family patents
